Cargando…

Matrix Metalloproteinase-3 in Myasthenia Gravis Compared to Other Neurological Disorders and Healthy Controls

MMP-3 is capable of degrading a variety of proteins, including agrin, which plays a critical role in neuromuscular signaling by controlling acetylcholine receptor clustering. High MMP-3 levels in a proportion of myasthenia gravis (MG) patients have been reported. A pathogenic role of MMP-3 in other...

Descripción completa

Detalles Bibliográficos
Autores principales: Luckman, Steven P., Gilhus, Nils Erik, Romi, Fredrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150147/
https://www.ncbi.nlm.nih.gov/pubmed/21826262
http://dx.doi.org/10.4061/2011/151258
_version_ 1782209505391542272
author Luckman, Steven P.
Gilhus, Nils Erik
Romi, Fredrik
author_facet Luckman, Steven P.
Gilhus, Nils Erik
Romi, Fredrik
author_sort Luckman, Steven P.
collection PubMed
description MMP-3 is capable of degrading a variety of proteins, including agrin, which plays a critical role in neuromuscular signaling by controlling acetylcholine receptor clustering. High MMP-3 levels in a proportion of myasthenia gravis (MG) patients have been reported. A pathogenic role of MMP-3 in other neurological disorders has been suggested but not proven. We have therefore examined the levels of MMP-3 in 124 MG patients and compared them to 59 multiple sclerosis (MS) patients, 74 epilepsy patients, 33 acute stroke patients, and 90 healthy controls. 15.3% of the patients in the MG group were MMP-3-positive (defined as higher than cutoff value 48 ng/mL) with very high mean MMP-3 concentration (79.9 ng/mL), whereas the proportion of MMP-3 positive patients in the MS (3.4%), epilepsy (6.7%), stroke (0%), and the control group (4.4%) was significantly lower. Mean MMP-3 concentration in the total MG group (25.5 ng/mL) was significantly higher than in the MS (16.6 ng/mL) and stroke (11.7 ng/mL) groups, but did not differ significantly from the epilepsy (19.4 ng/mL) and the control group (23.4 ng/mL). MMP-3 may have a specific pathogenic effect in MG in addition to being associated with autoimmune diseases in general.
format Online
Article
Text
id pubmed-3150147
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher SAGE-Hindawi Access to Research
record_format MEDLINE/PubMed
spelling pubmed-31501472011-08-08 Matrix Metalloproteinase-3 in Myasthenia Gravis Compared to Other Neurological Disorders and Healthy Controls Luckman, Steven P. Gilhus, Nils Erik Romi, Fredrik Autoimmune Dis Clinical Study MMP-3 is capable of degrading a variety of proteins, including agrin, which plays a critical role in neuromuscular signaling by controlling acetylcholine receptor clustering. High MMP-3 levels in a proportion of myasthenia gravis (MG) patients have been reported. A pathogenic role of MMP-3 in other neurological disorders has been suggested but not proven. We have therefore examined the levels of MMP-3 in 124 MG patients and compared them to 59 multiple sclerosis (MS) patients, 74 epilepsy patients, 33 acute stroke patients, and 90 healthy controls. 15.3% of the patients in the MG group were MMP-3-positive (defined as higher than cutoff value 48 ng/mL) with very high mean MMP-3 concentration (79.9 ng/mL), whereas the proportion of MMP-3 positive patients in the MS (3.4%), epilepsy (6.7%), stroke (0%), and the control group (4.4%) was significantly lower. Mean MMP-3 concentration in the total MG group (25.5 ng/mL) was significantly higher than in the MS (16.6 ng/mL) and stroke (11.7 ng/mL) groups, but did not differ significantly from the epilepsy (19.4 ng/mL) and the control group (23.4 ng/mL). MMP-3 may have a specific pathogenic effect in MG in addition to being associated with autoimmune diseases in general. SAGE-Hindawi Access to Research 2011-08-01 /pmc/articles/PMC3150147/ /pubmed/21826262 http://dx.doi.org/10.4061/2011/151258 Text en Copyright © 2011 Steven P. Luckman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Luckman, Steven P.
Gilhus, Nils Erik
Romi, Fredrik
Matrix Metalloproteinase-3 in Myasthenia Gravis Compared to Other Neurological Disorders and Healthy Controls
title Matrix Metalloproteinase-3 in Myasthenia Gravis Compared to Other Neurological Disorders and Healthy Controls
title_full Matrix Metalloproteinase-3 in Myasthenia Gravis Compared to Other Neurological Disorders and Healthy Controls
title_fullStr Matrix Metalloproteinase-3 in Myasthenia Gravis Compared to Other Neurological Disorders and Healthy Controls
title_full_unstemmed Matrix Metalloproteinase-3 in Myasthenia Gravis Compared to Other Neurological Disorders and Healthy Controls
title_short Matrix Metalloproteinase-3 in Myasthenia Gravis Compared to Other Neurological Disorders and Healthy Controls
title_sort matrix metalloproteinase-3 in myasthenia gravis compared to other neurological disorders and healthy controls
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150147/
https://www.ncbi.nlm.nih.gov/pubmed/21826262
http://dx.doi.org/10.4061/2011/151258
work_keys_str_mv AT luckmanstevenp matrixmetalloproteinase3inmyastheniagraviscomparedtootherneurologicaldisordersandhealthycontrols
AT gilhusnilserik matrixmetalloproteinase3inmyastheniagraviscomparedtootherneurologicaldisordersandhealthycontrols
AT romifredrik matrixmetalloproteinase3inmyastheniagraviscomparedtootherneurologicaldisordersandhealthycontrols